Irma Bagdoniene: Statin Intolerance – Challenges and Solutions
Irma Bagdoniene, Cardiologist Specializing in Prevention & Lipidology, shared on LinkedIn:
“Statin intolerance: a frequent clinical challenge, but far from a dead end.
True, confirmed statin intolerance with myopathy and CK elevation occurs in about 5% of patients reporting symptoms. Many are actually experiencing the well-documented nocebo effect.
For us, this does not mean stopping therapy. It means adapting our approach.
Most patients labeled ‘intolerant’ do well after switching to another statin (for example, hydrophilic rosuvastatin) or trying low-dose, alternate-day dosing.
For those truly intolerant, therapeutic options remain robust and effective:
• Ezetimibe lowers LDL-C by 15–20%
• Bempedoic acid reduces LDL-C by 15–25% without muscle-related symptoms
• PCSK9 inhibitors provide a powerful 50–60% LDL-C reduction
• Inclisiran, with just twice-yearly dosing, delivers sustained ~60% LDL-C lowering
The CLEAR-Outcomes trial also highlighted that in statin-intolerant patients, hsCRP may predict cardiovascular risk even better than LDL-C.
The take-home message: stopping lipid-lowering therapy should be avoided wherever possible. Re-challenge, switch agents, or refer to a lipid specialist — but never leave high-risk patients unprotected. •
A highly recommended statement on this from the National Lipid Association.”
Stay with Hemostasis Today to explore more from Irma Bagdoniene.
-
Aug 11, 2026, 08:07Nicola Pozzi: Advancing Hemostasis Through Scientific Collaboration at Hemostasis GRC
-
Aug 11, 2026, 07:50When Access to Care Changes Everything – WFH
-
Aug 11, 2026, 07:41Kevin Land: How Cellular Therapy Is Changing Transfusion Medicine
-
Aug 11, 2026, 07:35Kuldeep Singh Bhadauria: Building the Future of Hemophilia Care in India
-
Aug 11, 2026, 07:28Archil Jaliashvili: When Every Minute Matters Time Becomes a Therapy
-
Aug 11, 2026, 07:05Mavis Agnes Kisakye: Building Sustainable Transition Pathways in Hemophilia Care
-
Aug 11, 2026, 06:48Rishdha Roshad: What Happens to the Brain During Cardiopulmonary Bypass?
-
Aug 11, 2026, 05:53Isaac Okello: Strengthening Sickle Cell Advocacy in Uganda
-
Aug 11, 2026, 05:38Rami Unterman: A Simple New Biomarker for Fibrotic ILDs